Ironwood Pharmaceuticals (IRWD) Expected to Release Earnings on Thursday

Key Points

• Ironwood Pharmaceuticals is expected to report Q3 2026 earnings before the market opens on Thursday, November 5. Analysts anticipate EPS of $0.3233 and revenue of approximately $119.99 million.
• In its prior quarter, the company reported $0.31 EPS and $113.04 million in revenue, missing analyst estimates for both measures. Analysts expect full-year EPS of $1.10 but a loss of $0.03 per share next fiscal year.
• IRWD shares were down 3.3% to $3.50, while analysts maintain a “Moderate Buy” consensus rating and an average price target of $6.23.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.3233 per share and revenue of $119.99 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $113.04 million for the quarter, compared to analysts' expectations of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. On average, analysts expect Ironwood Pharmaceuticals to post $1.10 EPS for the current fiscal year and ($0.03) EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Down 3.3%

Ironwood Pharmaceuticals stock opened at $3.50 on Friday. Ironwood Pharmaceuticals has a 12 month low of $1.61 and a 12 month high of $5.78. The stock has a fifty day simple moving average of $3.96 and a two-hundred day simple moving average of $3.99. The firm has a market cap of $578.34 million, a price-to-earnings ratio of 4.55 and a beta of 0.21.

Analyst Upgrades and Downgrades

IRWD has been the topic of a number of research analyst reports. Wall Street Zen downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 5th. Weiss Ratings upgraded Ironwood Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Jefferies Financial Group raised Ironwood Pharmaceuticals to a "hold" rating in a research report on Friday, September 25th. Finally, Zacks Research lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $6.23.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood's principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.